It’s only a matter of time before 3D bio-printing really takes off. One of the leaders in the space is Organovo, a company who has already been able to 3D print living liver tissue, and has an ultimate goal of 3D printing a functioning liver for transplantation within a human being.
Before we get there though, there are many useful applications to 3D printed living tissue, which can already be used today. One such application is that of drug discovery testing. Every year billions of dollars are spent performing clinical trials on potential new drugs for the market. Many of these trials involve human beings, oftentimes being put at some risk. Liver toxicity testing, in particular, is usually performed using tissue samples from cadavers, meaning it’s not all that easy to obtain such samples. What 3D bio-printing enables researchers to do, is create live human tissue, which can then be used as a test bed to discover any negative reactions a particular drug may have on that tissue. Once scaled up, such a process could make available as much tissue as is needed for research, as well as tissue of extremely high quality.
Organovo has been leading the way in this space. They have been working for years to perfect the 3D printing techniques required to produce high quality tissue, which is able to stay alive over a long period of time. Today, the company announced an agreement with one of the largest pharmaceutical corporations on the planet, Johnson & Johnson. The actual agreement was signed between Organovo and Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson.
Under this agreement, of which the exact terms have not yet been disclosed, the companies will work together to evaluate the use of 3D bio-printed tissue in a drug discovery setting. Just what kind of tissue, and to what extent the testing will be done, is yet to be seen, however, it certainly bodes well for the progress of 3D bio-printing technology. To have a major, globally recognizable, corporation like Johnson & Johnson on board, could push the adoption of this technology, as well as its progress to a whole to level. It is interesting to note that following the release of an 8K filing disclosing this agreement this morning, shares of Organovo are up over 11%.
What will the implications of this agreement be? Let’s hear your opinions in the Organovo/Johnson & Johnson forum thread on 3DPB.com.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
HP and Global Steel Giant ArcelorMittal Announce Strategic 3D Printing Collaboration
Fortune Global 500 company ArcelorMittal, the world’s second-largest supplier of steel, has announced a strategic collaboration with HP to develop new additive manufacturing (AM) applications for ArcelorMittal’s steel powders. Via...
Tomorrow: AM Investment Strategies Returns with Free Online Executive Roundtable
With a new Trump Administration and uncertain economic markets, the 3D printing industry is at a pivotal point in its growth. There’s no one who knows this better than the...
3D Systems Expands Product Line ahead of Formnext 2024
At Formnext 2024, 3D Systems (NYSE: DDD) will be introducing a suite of new technologies and materials aimed at advancing production capabilities across additive manufacturing (AM) sectors. Showcasing developments in...
Metal Wire 3D Printer OEM ValCUN Announces Plans for 2025 Expansion
ValCUN, a Belgian original equipment manufacturer (OEM) of wire-based metal additive manufacturing (AM) hardware, has announced that the company has entered the next phase of its growth trajectory, making key...